Eli Lilly & Company (NYSE:LLY) ranks among the best set-it-and-forget-it stocks to buy. On June 27, UBS kept its Buy rating ...

The first study to put two GLP-1 weight loss drugs head-to-head found Zepbound helped people lose more weight than Wegovy.

Ginger also understands what it means to be a visible figure in the body-diverse community. Should she win All Stars 10, ...

Wall Street's smartest money has quietly amassed over $150 million in bullish positions, with Goldman Sachs eliminating all ...

Making a dagger or giant knife fit for 2020 with a real murder hornet cast in epoxy resin. This project embodies a unique ...

This video showcases the restoration of a rare Kelly Wood Slasher hewing axe from the 1900s. The restoration process includes ...

Both well-established and small, clinical-stage pharma companies are investing heavily to be able to someday compete with ...

A company expected to fare well during this time is Eli Lilly, with revenue forecast to improve by 165% in 2030. This will largely be driven by the company’s glucagon like peptide-1 receptor agonist ...

MariTide helped participants lose up to 20% of their body weight in a year-long trial. But it could be years before the new ...

They burst onto the scene four years ago and are taking over the pharmaceutical world. New GLP-1-based drugs like Ozempic, Wegovy or Zepbound are said to be a weight-loss game changer and could drive ...

UBS remains bullish on Eli Lilly’s future thanks to surging demand for its obesity and diabetes treatments. UBS predicts Zepbound sales could exceed market expectations by roughly 15%. Meanwhile, ...